Techno Medica (6678) Q1 2027 earnings summary

Executive summary

• Net sales for the quarter ended June 30, 2026, rose 25.3% year-over-year to ¥2,202 million.

• Operating profit reached ¥236 million, a significant turnaround from a ¥2 million loss in the prior year.

• Ordinary profit surged to ¥243 million from ¥23 million year-over-year.

• Net profit increased sharply to ¥158 million, up from ¥16 million in the same quarter last year.

• Basic earnings per share rose to ¥23.86 from ¥2.38 year-over-year.

Financial highlights

• Gross profit improved to ¥1,049 million from ¥811 million year-over-year.

• Selling, general and administrative expenses remained stable at ¥812 million.

• Total assets decreased to ¥16,239 million as of June 30, 2026, from ¥17,966 million at March 31, 2026.

• Net assets declined to ¥13,709 million from ¥14,410 million at the previous fiscal year-end.

• Equity-to-asset ratio improved to 84.4% from 80.2% year-over-year.

Outlook and guidance

• Annual dividend forecast for the fiscal year ending March 31, 2027, is ¥93 per share, down from ¥129 per share in the previous year.

• No revisions to the dividend forecast were announced.

• Management cautions that actual results may differ due to economic and market factors.